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1. Introduction 
All immune cell lineages arise from the multipotent stem cells in the bone marrow. The 
development and regulation of immune system cells (immune homeostasis) depends on the 
programmed appearance of specific cell surface molecules (e.g. receptors) and 
responsiveness to certain cytokines and chemokines. After maturation, the immune system 
cells include antigen presenting cells (APCs), other phagocytic cells like neutrophils, 
eosinophils, basophils and lymphocytes which include T lymphocytes, Β lymphocytes and 
natural killer (NK) cells. Depending on an initial stimulus and the microenvironmental 
conditions at a given time, each lymphocyte lineage can be subdivided to different 
populations with discrete specialized functions. Subpopulations of crucial importance are 
CD4+ T cells (mainly Th1, Th2, Th17 and T regulatory cells) and CD8+ T cells, CD16- and 
CD16+ NK cells and CD5+ and CD5- B cells. 
As a structure, the immune system consists of central locations of immune cell production 
and differentiation (bone marrow and thymus) and peripheral organs, where encounter 
with antigen and response to it occurs, that is the spleen, lymph nodes, tonsils and mucosa-
associated lymphoid tissue (MALT). Mucosal surfaces and the skin provide the main 
primary access for foreign antigens to meet cells of the immune system, where they first 
react primarily with APCs. 
Innate immunity includes skin and mucosal barriers, as well as the innate immune cells that 
are triggered and react in minutes after they encounter ‘foreign’ material. The innate 
immune system, as it represents the first line of host defense against foreign entities, is 
regarded as a nonspecific system and its main role is to engulf and eliminate pathogens, 
trigger pro-inflammatory responses and present antigens to adaptive immune cells, which 
are subsequently activated. More recently it has been shown that the innate immune system 
has a necessary degree of specificity that enables it to discriminate between self and foreign 
particles (e.g. microorganisms). Germline encoded and constitutively expressed pattern 
recognition receptors (PRRs)- like Toll receptors on innate immune cells, help them to 
discriminate highly conserved pathogen associated molecular patterns (PAMPs), which activate 
specific signaling pathways that lead to robust but well-defined innate immune responses. 
Research on innate immunity is progressively uncovering molecular and cellular 
mechanisms by which it recognizes environment and reacts to it, leading to protective or 
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pathological and harmful immune responses. Understanding innate and adaptive immunity 
pathways in detail will have a great impact on revealing the immunopathology of immune-
mediated diseases like Adamantiades-Behcet Disease (ABD) and developing more targeted 
immunotherapeutic agents to manipulate, even life-threatening, ABD vasculitis.     
2. General considerations in ABD immunopathogenesis 
ABD owes its name to Benediktos Adamantiades (Greek ophthalmologist), who had 
described it first in 1930 and Hulusi Behcet (Turkish dermatologist), who described 
hypopyon, iritis and orogenital aphthosis in 1937 (Adamantiades, 1931; Behcet, 1937). 
However, the first description of the disease dates back, 2500 years, to Hippokrates, to the 
5th century BC, in the Epidemion book, case 7, where it is described as aphthous ulceration, 
genital ulceration and iridocyclitis.  
There were other forms of fever… 
Many developed aphthae, ulcerations… 
Many ulcerations about the genital parts… 
Watery ophthalmies of a chronic character, with pains… 
Since the early descriptions, additional clinical features have been described and added to 
disease spectrum. ABD can be manifested with different organ involvement, articular, 
neurological, pulmonary and gastrointestinal, besides the classical clinical triad proposed by 
the International Study Group for Behcet’s Disease. 
Nowadays, ABD diagnosis rests upon a set of established criteria, where no single clinical or 
laboratory feature is pathognomonic (International Study Group for Behcet’s Disease, 1990, 
Table 1). 
 
Recurrent oral ulcerations plus two Recurrent genital ulcers 
 Skin lesions (erythema nodosum, acne, 
folliculitis)  
 Ocular lesions (uveitis) 
 Positive pathergy test 
Table 1. Diagnostic Criteria for ABD 
From early descriptions, it was shown that patients with ABD cluster according to a 
geographic pattern that coincides with the ancient “Silk Route”. It has a higher incidence 
(100 times more common) in the countries of the Mediterranean Basin, Middle East and Far 
East, which includes Greece, Turkey, Saudi Arabia, Iran, Korea ,China and Japan while it is 
rare in North America. Although sporadic cases are described, there is an increased 
frequency among relatives (familial aggregation), mainly in HLA-B51 class I gene positive 
relatives. Genetic susceptibility factors seem to be connected with more severe disease 
expression. Particularly, in Asia, up to 80% of patients are HLA-B51 positive. Recent studies 
focus on new genetic markers that could amplify immune responses responsible for disease 
expression (HLA and non-HLA genes), probably under an environmental challenge e.g. an 
infectious agent (the infectious model), (Fietta, 2005; Kaklamani et al, 1998; Verity et al, 2003; 
Yazici H et al, 1999). 
ABD etiopathogenesis still remains a mystery to be elucidated. There is substantial evidence 
for an infectious background participating in disease initiation, especially, in genetically 
predisposed individuals. A number of viruses like HSV, Parvovirus B19 or bacteria like 
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uncommon serotypes of Streptococcus have been implicated. At the moment there is no 
concrete proof of the existence of certain microorganisms in the etiology of ABD and the 
initiation of the immunological process. Molecular mimicry between bacterial (HSV, 
streptococci) and human heat shock proteins (HSP), due to significant peptide homology 
between bacterial and human HSPs has been widely accepted, might be the basic  
link between infection and (auto)immunity in predisposed subjects, and could initiate and 
augment T and B cell immune responses. Besides, the option of exposure to chemicals  
was not supported for long. However, although immunological abnormalities concerning 
innate and adaptive immunity in ABD have been extensively studied, there is no adequate 
proof that ABD is either a typical autoimmune disease- it does not fulfill substantial  
criteria- or an auto-inflammatory disease- it is a very weak hypothesis at the moment 
(Direskeneli & Saruhan-Direskeneli, 2003; Kapsimali et al, 2010; Mumcu et al, 2007; 
Zouboulis & May, 2003).  
ABD is a systemic vasculitis which may affect arteries and veins of all sizes in any organ  
and underlies disease manifestations. To a great extent, disease pathology points to  
a vascular inflammation. Biopsies of affected organs usually reveal vasculitis, where intense 
infiltrations of neutrophils predominate and CD4+ T lymphocytes are present in the  
early stages. 
Venous vascular involvement and thrombosis is the characteristic feature of the disease, 
probably responsible for most of the tissue damage seen. Inflammatory changes in large 
arteries are typical of vasculitis, lack wall thickening and granuloma formation and have a 
tendency towards aneurysm formation. It is more severe in males. ABD lacks an increased 
risk of atherosclerosis. The term ‘vasculo-Behcet’ has been adopted to describe cases where 
vascular features dominate in disease expression. After initial vascular lesion (usually 
venous thrombosis), other vascular lesions may follow and lead to progressive, multifocal 
vascular disease with an unfavorable prognosis (Melikoglu et al, 2008). 
Vascular inflammation is mainly due to complex innate-immune, pro-inflammatory 
mechanisms which activate and perpetuate adaptive/specific immune responses against 
antigens not identified clearly. Endothelial dysfunction, partly due to anti-endothelial 
autoimmune reactions and non-specific coagulation/fibrinolytic abnormalities, has also 
been demonstrated and participates in disease pathophysiology to some extent. In such 
cases aggressive treatment consisting of immunosuppressive drugs is recommended 
(Calamia et al, 2011; Calamia & Kaklamanis, 2008).  
Management decisions are often difficult to take and there is a lack of controlled trials. A 
sequential therapeutic approach, based on ABD immunopathology and the 
immunomodulatory action achieved by immunosuppressive drugs is discussed. 
2.1 Innate immunity cells abnormalities in ABD 
Neutrophil involvement in ABD pathogenesis represents a challenging issue, as neutrophil 
hyperactivation seems to play a pivotal role in the inflammatory vasculitic characteristics of 
disease lesions. Neutrophils are the dominant subpopulation of the inflammatory infiltrates 
in the vessel wall (Hayasaki et al, 2004).   
Neutrophil hypereactivity is a major contributor to the well-known pathergy skin reaction, 
which might be positive during periods of active disease. Pathergy reaction is a non-specific 
skin hyper-reactivity to minor trauma, such as a needle prick (Boura et al, 2007; Ozdemir et 
al, 2007).  
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At the tissue level, neutrophils were described to be present in the anterior chamber of the 
eye and the corneal epithelium, as well as in the ciliary body and chorioid tissue (Mendoza-
Pinto et al, 2010). 
These cells are reported to be functionally impaired in the disease. Eksioglu-Demiralp et al 
described specific defects concerning neutrophil activation, oxidative burst and phagocytic 
activity (Eksioglu-Demiralp et al, 2001). On the other hand, increased synthesis of reactive 
oxygen species (ROS) has been reported in ABD. ROS-mediated oxidative stress seems to 
play an important role in pathogenesis, as advanced oxidation protein products were 
described to correlate with disease activity (Yazici C et al, 2004). This contradiction might 
mean that functional activity of neutrophils might correlate to disease activity or other, 
poorly defined, parameters.   
Additionally, it has been postulated that endothelial cells cooperate with neutrophils  
and monocytes in the vasculitic process. Endothelial cell activation and subsequently 
increased expression of cell adhesion molecules is a characteristic feature of the disease, 
which can trigger neutrophils and monocytes to initiate natural immune responses on the 
vessel wall. Recently, a novel mechanism by which neutrophils may interact with cytokine-
activated endothelial cells in the presence of anti-endothelial cell antibodies has been 
described. Main receptors were Fc-gamma-RIIa and CXCR1/2. Moreover, endothelium 
activation leads to excessive thrombin formation and impaired fibrinolytic function, thus 
contributing to the generation of a prothrombotic state in ABD (Florey et al, 2007; Lee MT et 
al, 2007; Probst et al, 2004).  
Furthermore, neutrophils are primed by overproduced pro-inflammatory cytokines, 
secreted by antigen presenting cells (APCs) and the endothelium (e.g. TNF-ǂ, IL-1,  
IL-6, IL-8 etc). Under such conditions, they secrete other cytokines that prime themselves, 
cause Th1 polarization and maintain a non-specific, pro-inflammatory microenvironment 
to retain enhanced activity (Carletto et al, 1997; Katsantonis et al, 2000; Zouboulis et  
al, 2000). 
Recently, the role of matrix metalloproteinases, particularly MMP-2 and MMP-9 was 
underlined in ABD. Pay et al found increased levels of these molecules in the serum of ABD 
patients and this was strongly correlated to vasculo-Behcet disease, especially aneurysm 
formation. Other investigators confirmed the elevated MMP-9 levels in the cerebrospinal 
fluid of ABD patients, suggesting that they might be involved in the pathogenesis of neuro-
ABD (Hamzaoui K et al, 2009; Pay et al, 2007). 
It is reported that neutrophils are more resistant to spontaneous apoptosis (via Fas/Fas 
ligand interactions) during the remission of ABD uveitis, while resistance was restored in 
the active phase of the disease (Fujimori et al, 2008). 
Monocytes are also involved in ABD pathogenesis. Recent studies support the possible role 
of bacterially-induced innate immune responses through monocyte Toll-like receptor (TLR) 
activation. It was reported that TLR-2 was decreased after stimulation with LPS and HSP-60, 
or increased after bacterial lipoteichoic acid stimulation. TLR-6 expression was found to be 
enhanced after stimulation with HSP-60 and Streptococcus sanguis (Neves et al, 2009; Yavuz 
et al, 2008). As mentioned above, HSP-60 and Streptococcus sanguis represent candidate 
antigens in ABD pathogenesis.    
Antigen-presenting cells are reported to be activated in ABD patients, since ex vivo cultured 
monocytes were able to produce increased amounts of TNF-ǂ, IL-6 and IL-8 (Mege et al, 
1993). Moreover, there is strong evidence suggesting that APCs may be primarily involved 
in ABD immunopathogenesis. Early data comes from pathergy reaction histology, where 
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Saito et al showed that Langerhans cells were increased in the dermis layer shortly after 
needle prick (Saito et al, 1980).   
However, it has not been clarified whether APC hypereactivity is a primary defect of these 
cells or the result of disease related conditions. Nevertheless, IL-12 and IL-18, cytokines 
mostly produced by APCs, are known to strongly promote Th1 polarization of immune 
responses. Both these cytokines have been found in increased levels during active disease, 
implying a central role for APCs in ABD pathogenesis (Hamzaoui K et al, 2002). 
Finally, Pay et al described decreased numbers of peripheral plasmacytoid dendritic cells, 
along with decreased levels of IFN-ǃ and suggested that this cell subset may also participate 
in disease pathogenesis (Pay et al, 2007).   
2.1.1 Gamma-delta (γδ) T cells 
These specialized T cells (TCR comprising of Ǆ and ǅ heterodimer) have been increasingly 
investigated during recent years. They are thought to play a critical role in mucosal 
immunity, being the first line of defense against invading micro-organisms, as well as the 
link between innate and adaptive immune response (Casetti et al, 2008).  
A subset of Ǆǅ T cells (Vgamma9+Vdelta2+) was found in increased numbers in the blood of 
active ABD patients. These cells were reported to express IL-2 receptor and HLA-DR surface 
molecules, indicating a high activation status. The Vgamma9+Vdelta2+ T cells were 
described to infiltrate target organs, such as the eye, while other studies found that they 
strongly proliferate after stimulation with bacterial extracts of the oral flora (Bank et al, 2003; 
Verjans et al, 2002; Yamashita et al, 1997).  
The critical role of gammadelta T cells in ABD is underlined in the study of Treusch et al, 
who found a decrease in their numbers after treatment with interferon-alpha-2a (Treusch et 
al, 2004).  
Later, it was shown that expanded CD56+ and CD8+ gammadelta T cells in ABD were 
capable of secreting IFN-Ǆ and TNF-ǂ. Data is further supported by the fact that these cells 
seem to be polyclonally rather than oligoclonally activated in ABD patients with oral ulcers. 
Probably because of repeated inflammation of the oral mucosa, due to a wide variety of 
antigenic stimuli, activation and proliferation of these cells might play a role in disease 
clinical heterogeneity (Freysdottir, 1999, 2006).  
2.1.2 NK and NKT cells 
Early studies reported an increase in NK cell numbers in ABD patients. However, others 
described a decrease in their cytotoxic activity in the active phase of the disease, which was 
restored in remission periods. However, recent studies reported that, although increased in 
active disease, NK cells do not seem to exert impaired cytotoxic activity, as they were shown 
to adequately suppress IFN-Ǆ production by CD4+ T cells, thus regulating a Th1 response in 
ABD (Onder et al, 1994; Suzuki et al, 1992; Yamaguchi et al, 2010).      
Natural killer T cells (NKT) comprise a sublineage of T cells that share characteristics of 
conventional T cells and NK cells and bridge innate and adaptive immunity. Their 
activation is restricted by the MHC molecule CD1d. Early studies reported an increase of 
CD4+CD16+ and CD4+CD56+ T cells in ABD. Other investigators confirmed the presence of 
increased CD56+ T cells in the periphery of patients with active ABD uveitis, in contrast 
with other forms of immune-mediated uveitis (Eksioglu-Demiralp et al, 1999; Yato & 
Matsumoto, 1999). 
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In the tissue level, NKT cells were found to be increased in the aqueous humor of uveitis 
patients. Additionally, in neuro-ABD patients, NKT cells were reported to be decreased in 
the periphery and increased in the cerebrospinal fluid, thus suggesting a recruitment of 
these cells in the site of inflammation. It should be mentioned that these cells were strongly 
Th1 polarized. Further studies demonstrated that CD8+CD56+ T cells represent potent 
cytotoxic effectors in ABD uveitis, as they were found to express both surface FasL and 
preformed intracellular perforin (Ahn et al, 2005; Hamzaoui K et al, 2006; Yu et al, 2004).  
2.2 Adaptive immunity cells abnormalities in ABD 
Although the exact pathogenetic mechanisms behind ABD remain to be fully elucidated, 
much evidence has been accumulated regarding the involvement of adaptive immune 
response in the disease. Recent studies have revealed the central role of T-cell mediated 
immunity; in parallel, histopathological studies have demonstrated, mainly, T-cell-
dominated perivascular infiltrates in skin, oral lesions and retina, as well as in choroids and 
periretinal scar tissue (Charteris et al, 1992a, 1992b; Gul et al, 1995, Poulter & Lehner, 1989). 
2.2.1 T cell abnormalities 
CD4+ T helper cells differentiate into, at least, four distinctive functional subsets, namely 
Th1, Th2, Th17 and T regulatory cells (Mucida & Cheroutre, 2010). For all of these 
lymphocyte subpopulations quantitive and/or qualitive abnormalities have been shown in 
ABD (Chi et al, 2008; Hamzaoui K et al, 2006, Ilhan et al, 2008; Mantas et al, 1999).  
Genetic and environmental factors may have an influence independently or in association 
with other parameters, such as the ligation of T-cell receptor (TCR), the activation of co-
stimulatory molecules, the predominance of a given cytokine in the microenvironment and 
others (Direskeneli et al, 1999).  
Many investigators suggest that a Th1 polarization of the immune response is present, at 
least, in active ABD. Th1 type proinflammatory cytokines, such as IL-2 and IFN-Ǆ, are 
reported not only to be increased in peripheral blood of patients with ABD, but also to 
correlate with disease activity. Additionally, IL-12, which drives Th1 immune response from 
naïve T cells, is also reported to be elevated in ABD. Interleukin-12 is suggested to play a 
substantial role in ABD; when recombinant IL-12 was added to peripheral blood 
lymphocytes from patients with active disease, it prevented spontaneous and Fas-induced 
apoptosis, resulting to proliferation of autoreactive Th1 lymphocytes that could contribute 
to a prolonged autoimmune inflammation (Esin et al, 1997; Frassanito et al, 1999; Nara et al, 
2008; Sugi-Ikai et al, 1998).  
Recently, IL-15 was reported to be increased in ABD, either in serum or in the aqueous 
humor of uveitis patients; IL-15 is able to induce pro-inflammatory cytokines, such as TNF-ǂ 
and IL-1ǃ, and facilitate maintenance of auto-reactive CD8+ T cells (Curnow et al, 2008; 
Waldman, 2004). 
The Th1 cells were proven to expand with high individual variability of the Vǃ  
TCR, suggesting that there is no single antigen responsible for T cell activation (Direskeneli 
et al, 1999).  
Histopathological studies also point to a Th1 type tissue infiltration in ABD, possibly driven 
by the highly expressed IL-12 and IL-23 in intestinal and cutaneous lesions. Interestingly, 
both streptococcal antigens and auto-antigens, such as aB-crystallin also drive an IL-12 
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mediated response in ABD (Imamura et al, 2005; Kulaber et al, 2007; Lew et al, 2008; 
Yanagihori et al, 2006).  
Concerning Th2 type of immune response, both, cells and signature cytokines, such as  
IL-4, IL-10 and IL-13 are reported to be unaffected or decreased in ABD by most researchers 
in the serum or in the aqueous humor. However, other studies reported a significant 
expression of IL-4 in oral ulcers from ABD patients, suggesting the presence of a  
more complex antigenic stimulus during the disease (Ahn et al, 2006; Dalghous et al, 2006, 
Mantas et al, 1999).  
Th17 cells represent a relatively new functional subset of T helper cells, which mainly 
produce IL-17A-F, IL-22, IL-23 and TNFa. Interleukin-6 and TGF-ǃ are considered to be the 
major cytokines responsible for the differentiation of these cells from naïve T cells. Recent 
studies have shown a possible role for these cells in the majority of systemic and organ-
specific autoimmune diseases (Mesquita et al, 2009).  
Concerning ABD, active disease is characterized by high serum levels of IL-6 and IL-17, 
compared to patients in remission, while serum levels of IL-23 and IL-17 are reported to be 
elevated in active uveitis. However, an increased Th17 response is not confirmed by all 
studies (Chi et al, 2008; Ferrante et al, 2010; Saruhan-Direskeneli et al, 2003).  
Recent papers underline Th17 involvement in disease pathogenesis in the context of their 
ratio to Th1 cells. Kim et al reported an increased peripheral Th17/Th1 ratio, especially in 
uveitis and folliculitis patients, while there were no significant differences concerning 
Th1/Th2 and Th17/Th2 ratios (Kim et al, 2010). Histopathological studies, however, did not 
confirm these results in the tissue level (Canete et al, 2009). 
Cytotoxic T cells are also reported to be activated in ABD, probably as a response to a 
profound inflammation. CD8+ T cells were also found in increased numbers in the aqueous 
humor in uveitis patients. Furthermore, recent studies support that these cells play a 
fundamental role in ABD flares, as they were found in increased numbers in active disease, 
along with ǄǅT cells. Additionally, CD8+ T cells were shown to express the CD69 molecule 
(early activation marker), while their numbers and function returned to normal after 
successful management of the disease flare (Houman et al, 2004; Yasuoka et al, 2008).       
2.2.2 Immune regulation in ABD 
Firstly described by Sakaguchi et al in the ‘70s, T regulatory cells represent potent regulators 
of the immune response. These cells are divided into two broad categories, namely the 
“naturally occurring” and the “inducible” T regulatory cells (Sakaguchi et al, 1995).   
Interest for immune regulation in ABD intensified as early as 1982, when Victorino et al and 
Sakane et al independently reported abnormal T cell suppressor activity (Sakane et al, 1982; 
Victorino et al, 1982). Recent studies were not able to definitely shed light in this issue. 
Paradoxically, CD4+CD25+FoxP3+ T regulatory cells were reported to be increased in active 
ABD compared to inactive disease and healthy controls, while they could suppress their T 
effector cell counterparts. The authors suggested that this may be due to the need for 
inflammation suppression in ABD (Hamzaoui K et al, 2006).  
On the other hand, other investigators showed that T regulatory cells were significantly 
decreased before ocular attack in ABD patients, suggesting that they may serve as a 
predictive marker in ocular disease, thus, allowing treatment intensification before relapse 
(Nanke et al, 2008). 
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The exact interactions between T regulatory cells and other immune cells in ABD are not 
well understood. Hamzaoui suggested a possible cross talk between these cells and NKT 
cells, as these subpopulations can modulate each other through cell-to-cell contact and IL-2 
dependent mechanisms, respectively (Hamzaoui K, 2007). Furthermore, other cells with 
possible regulatory activity, such as gammadelta-T-cells were reported to be incapable of 
maintaining a regulatory profile in ABD (Clemente et al, 2010). 
T regulatory cells represent a promising therapeutic target for suppressing inflammation in 
ABD. Recently, Sugita et al reported T-reg expansion after in vitro stimulation with 
infliximab and significant suppression of bystander T effector cells in active ABD uveitis 
(Sugita et al, 2011). Additionally, other investigators reported that vitamin D is an important 
promoter of T cell regulation in vivo in ABD patients, as its levels were strongly correlated 
to T regulatory cells (Hamzaoui K et al, 2010).  
2.2.3 B cell abnormalities and autoantibodies in ABD 
Although not a typical autoimmune disease, ABD is characterized by B cell activation, 
despite the absence of disease-specific autoantibodies. Early studies demonstrated that the 
total numbers of B cells were normal during the disease; however, an increased 
expression of activation markers, such as CD13, CD133, CD80 and memory marker 
CD45RO was reported. Despite the presumed B cell activation, plasma cells were found  
in low levels, in contrast to other well-defined autoantibody-mediated disorders. These 
results suggest a modified B cell function in ABD, although it is not known if it is related 
to a weak stimulus by an unknown external antigen or it represents an epiphenomenon  
in the context of the general dysfunction of the immune system (Eksioglu-Demiralp et  
al, 1999). 
After the identification of the multiple roles of B cells in the immune response, such as 
antigen presentation and cytokine release, newer studies reported some interesting results. 
B cells (along with plasma cells) were found in histopathological studies in the synovium, 
the central nervous system and the vessel wall of patients with ABD (Hirohata, 2008; 
Hirohata & Kikuchi, 2009; Suh et al, 2001).  
Furthermore, it was recently reported that B-cell activating factor (BAFF) receptor was 
upregulated on B cells in patients with ABD vasculitis, as well as serum BAFF levels and 
mRNA in skin biopsies. Later, Hamzaoui A et al showed that BAFF, along with IL-6 and IL-
13, were, also, increased in the broncho-alveolar lavage (BAL) fluid from ABD patients with 
active pulmonary involvement; All these factors are known to actively participate in the 
maturation and activation of B cells (Hamzaoui A, 2010; Hamzaoui K, 2008).  
Consequently to B cell activation, various autoantibodies have been detected in the sera  
of ABD patients; however, their role in disease pathogenesis remains to be defined. 
Antinuclear antibodies (ANA) and rheumatoid factors are typically absent. On the  
other hand, autoantibodies against cell surface antigens, such as anti-endothelial cells 
antibodies (AECA), or against mucosal antigens have repeatedly been reported. Recent 
studies, based on proteomics, have revealed the presence of antibodies against more specific 
antigens, such as ǂ-enolase, ǂ-tropomyosin, kinectin, selenium-binding protein, esterase-D 
and carboxy-terminal subunit of Sip-1 (Delunardo et al, 2006; Direskeneli et al, 1995; Lee KH 
et al, 2003; Lu et al, 2005; Mahesh et al, 2005; Michelson et al, 1985; Mor et al, 2002; Okunuki 
et al, 2007, 2008). 
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Concerning AECA, their prevalence in ABD is reported to vary from 18-50%; however, 
difficulties in method standardization led to significant discrepancy between the different 
studies and raised concerns about their clinical utility. Furthermore, other studies confirmed 
that AECA were not quite specific for the disease; instead, they are frequently detected in 
other systemic vasculitides and/or autoimmune diseases. Despite their inspecificity, AECA 
were shown to mediate enhanced polymorphonuclear adhesion to activated endothelial 
cells, thus promoting tissue injury during systemic inflammation. An association between 
IgG-AECA and central nervous system involvement in ABD was reported (Dinc et al, 2003; 
Souza et al, 2007; Zeng et al, 2004).  
Alpha-enolase represents a target antigen of IgM AECA, reported to be detectable in 
approximately half of ABD patients, especially in those with overt vascular involvement; 
however, its specificity is not satisfying (Lee JH et al, 2009).  
3. Coagulation and fibrinolytic abnormalities in ABD 
Although no specific defect in the coagulation cascade has so far been detected, ABD is 
characterized by thrombotic manifestations in 7-38% of the patients. In most studies, both 
coagulation and fibrinolytic pathways seem to be activated (Leiba et al, 2004). 
Various pro-coagulant conditions, such as deficiencies of protein C, protein S, antithrombin 
III and factor V Leiden and prothrombin G20210A mutations have been described in ABD 
patients (Ates et al, 2003; Caramaschi et al, 2010). Additionally, higher levels of 
homocysteine, factor VIII, thrombin-antithrombin III complexes (TAT) and prothrombin 
fragment 1+2 maintain the intravascular generation of thrombin in these patients (Espinosa 
et al, 2002; La Regina et al, 2010). Despite all these data, it seems that thrombophilic factors 
do not play a major role in the thrombotic tendency of ABD. Leiba et al, in a tightly designed 
study, showed that the only factor that was strongly correlated to thrombosis in these 
patients was hypertriglyceridemia (Leiba et al, 2004). Other studies reported that active ABD 
patients were characterized by hypertriglyceridemia, low HDL and high Lp(a) levels 
(Musabak et al, 2005).  
Regarding the fibrinolytic cascade, most studies have revealed defective fibrinolysis with 
lower levels of tissue plasminogen activator (t-PA) and increased thrombin activatable 
fibrinolysis inhibitor (TAFI) and thrombomodulin. Other studies involve the plasminogen 
activator inhibitor (PAI), as this molecule appears to be increased in ABD, resulting in 
defective tPA/PAI complex formation (Donmez et al, 2010; Ozturk et al, 2004). Furthermore, 
the endothelial dysfunction due to immune-mediated vasculitis may also play an important 
role in the thrombotic tendency of the disease. 
Another important thrombogenic factor in ABD is the presence of antiphospholipid 
antibodies. Indeed, anticardiolipin (ACA) and anti-ǃ2-glycoprotein 1 (anti-ǃ2-GPI) 
antibodies, as well as lupus anticoagulant (LA) have been described in selected ABD 
patients (Bonnet et al, 2004; Kandolf-Sekulovic et al, 2005). Additionally, newer epitopes, 
such as antibodies against the phosphatidylserine-prothrombin complex (anti-PS/PT) or 
annexin V, have also been reported to be associated with thrombosis in these patients (Aslan 
et al, 2004; Kawakami et al, 2009). The significance of these antibodies in thrombotic 
manifestations of ABD remains to be fully elucidated. 
In Table 2, a synopsis of the main abnormalities of the immune cells in ABD is presented. 
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Neutrophils Hyperactivation 
Cytokine and MMPs secretion 
Resistance to apoptosis 
Tissue infiltration 
Monocytes/Macrophages Altered TLR expression 
Secretion of IFN-Ǆ, IL-1, IL-8, IL-12, TNF-
ǂ 
Gammadelta T cells Vgamma9+Vdelta2+ expansion 
Secretion of IFN-Ǆ, TNF-ǂ 
Polyclonal proliferation 
NK cells Increased numbers 
Impaired cytotoxic activity? 
Abnormal KIR repertoire 
NKT cells Recruitment to the site of inflammation 
High expression of FasL and perforin 
Interaction with T regulatory cells? 
CD8+ T cells Increased numbers 
Highly activated (CD69)  
CD4+ T cells (Th1 polarized) Secretion of IL-2, IL-12, IFN-Ǆ 
Resistance to apoptosis 
Tissue infiltration 
CD4+ T cells (Th17 polarized) Disease initiation? 
Secretion of IL-17, IL-23 
Increased Th17/Th1 ratio 
T regulatory cells Probably low numbers during active 
disease 
Impaired suppressive activity? 
B cells Normal numbers, but activated 
Increased expression of BAFF receptor 
Autoantibody production (AECA and 
others) 
Table 2. Main abnormalities in immune cells in ABD 
A proposed model for ABD vasculitis pathogenesis 
(schematic representation -1, -2, -3) 
In genetically predisposed individuals, due to an exogenous stress, e.g. an infectious insult, 
a systemic or local non-specific immune response is mediated via innate immune cells and 
the endothelium.  
Respiratory burst products and proinflammatrory cytokines and chemokines secreted at the 
site of the initial insult further attract   monocytes, neutrophils and dendritic cells around 
the area and the blood-endothelial barrier breaks down (schematic representation -1). 
Initial insult is neutralized, but HSPs derived from bacterial load, as well as HSPs from 
affected tissue/s give rise to a second, more specific T-cell-mediated immune response, 
according to molecular mimicry and/or epitope spreading model. These events might be 
augmented and spread out in case of repeated antigenic stimuli (second hit). Endothelial-
innate cell contact and activation perpetuates the proinflammatory milieu and along with 
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local tissue injury produces a ‘danger model’ situation, where APCs, through PAMP-PRR 
cross-talk, are activated and induce downstream Th1 and Th17 polarization of the specific 
immune response. Main cytokines mediating this process are IL-1, TNF-ǂ, IL-6, IL-8, IL-12, 
IL-18 and others, (schematic representation -2). 
T cells, through this antigen-driven activation, are committed and clonally expanded against 
certain candidate peptides via well known mechanisms of molecular cross-reactivity. The 
orchestrated immune reaction involves B cells activated by CD4+ T cells to produce 
autoantibodies (AECA?) that are able to induce endothelial damage and contribute to 
neutrophil migration as well. 
Gammadelta-Τ-cells probably contribute to the pathogenetic process, by cytokine secretion 
which augments Th1 polarization. The role of cell-mediated cytotoxicity is not clear at the 
moment. Probably, CD8+, NK and NKT cells are recruited in the site of inflammation and 
mediate a cytotoxic immune response.  
Hyperactivated neutrophils, primed by cytokines and the activated endothelium 
(overexpressing cell adhesion molecules), migrate into the vessel wall and produce 
reactive oxygen species and MMPs, thus contributing to vasculitic lesions and aneurysm 
formation. 
Additionally, low numbers or defective function of T regulatory cells probably cannot 
adequately regulate the hyperactivation status of effector cells, (schematic representation -3). 
Finally, during disease perpetuation, tissue damage may produce new epitopes (damage-
associated molecular patterns, DAMPs) that can further augment immune cells activation 
and contribute to the clinical heterogeneity of the disease. 
This pathogenetic model is briefly presented in Figure 1. 
 
 
Fig. 1. Proposed pathogenetic model of ABD vasculitis 
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4. Therapeutic approach to ABD vasculitis 
4.1 General principles 
Although treatment of ABD was reviewed recently, management of complicated cases, 
especially those with vascular involvement, still poses a great challenge to experienced 
physicians. Nowadays, the recently published EULAR (European League Against 
Rheumatism) recommendations are considered to be the accepted guidelines for the 
management of the disease. Nonetheless, treatment concerning vascular involvement, either 
major vessel or visceral disease (medium-small vessel vasculitis) is largely based on expert 
opinion and uncontrolled evidence from open trials and observational studies. So the need 
for further properly designed controlled clinical trials is obvious (Hatemi et al, 2008).  
In general, topical therapy should be applied in mucocutaneous lesions and should be the 
only treatment for mild symptoms. Although antiseptics seem to prevent secondary 
infections and reduce pain intensity, antibiotics face antigen burden and they are important 
in identifying disease relapses as well. Drugs with anti-inflammatory action are used as 
adjuvants but, beyond this, it is imperative to emphasize that the physician must be vigilant 
for alarming clues of systemic vasculitis and ready to implement immunomodulating 
regimen (Alpsoy, 2005; Alpsoy et al, 2007). 
Treatment decisions depend on the age, sex, comorbidities, patient’s willingness to 
cooperate and other parameters, such as the site and severity of involvement, as well as  
the frequency of recurrences. Fortunately, a part of disease burden can be managed with 
mild systemic immunosuppression. Early and aggressive immunosuppression is mandatory 
in severe or life- threatening cases. Below, the most commonly used immunomodulating 
drugs for the management of major vessel disease or visceral involvement will be discussed. 
(Table 3) 
4.2 Glucocorticosteroids (C/S) 
It is well known that glucocorticosteroids modify immune response to diverse stimuli by 
suppressing inflammatory reactions in general. They have profound metabolic effects and 
they affect the replication, movement and activity of virtually all cells involved in 
inflammatory process. Although   C/S exert cytotoxic effects to activated T cells at high 
doses, their immunomodulating effects are probably mostly attributed to their ability to 
modify cellular immune functions when low doses are used orally. At the cellular level C/S 
bind to their intracellular receptor forming an active complex. The complex moves to the 
nucleus, where it binds to DNA sequences modifying chromatin structure and altering the 
transcription machinery. Another mechanism of action is that glucocorticosteroids-
glucocorticosteroids receptor complex directly increases IκB (inhibitory factor κB) 
expression. IκB inhibits the actions of transcription nuclear factor NFκB. It is well known 
that NFκB promotes gene induction of cytokines, chemokines and adhesion molecules, thus 
amplifying lymphocyte proliferation and leading to the perpetuation of the inflammatory 
process (Bruton et al, 2005; Rhen & Chidlowski, 2005). 
Through these mechanisms C/S suppress cellular immunity, both Th17 and Th1 responses. 
This action explains their therapeutic use in ABD. Although more detailed trials are needed, 
worldwide clinical experience has shown that C/S are the cornerstone of treatment for 
many ABD complications.  High oral doses, up to 100mg/day for a long period of time, or 
pulse treatment with 1gr/day for 3 consecutive days or more are given, in serious or life-
threatening cases, like aneurysm formation or cavernous sinus thrombosis (Hatemi et al, 
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2008). It was demonstrated that in large-vessel arterial disease (arterial occlusion or 
aneurysm) high dose glucocorticosteroids alone did not improve occlusive disease and 
mortality (Li Thi Huong et al, 1995). On the contrary, other studies have shown that C/S in 
combination with other immunosuppressants had a significant beneficial effect in vascular 
complications of ABD (Alpsoy & Alkman, 2009, Sharaf & Yazici, 2009). In another recently 
conducted randomized trial, low dose intramuscular depot C/S was used and proved to be 
beneficial in milder manifestations, like erythema nodosum, but no for genital ulcers. The 
trial used the drug in depot form for intramuscular injection, so no conclusions can be 
drawn for the efficacy of the usual oral or intravenous regimen (Mat et al, 2006).   
Adverse effects such as osteoporosis, metabolic disturbances, psychosis must been taken 
into account. EULAR committee recommends the use of C/S as a first line therapy for 
managing all ABD manifestations. Different level of evidence for every case is probably 
attributed to data availability. Based on immunopathology and clinical data, we suggest the 
administration of high dose intravenous corticosteroids for the achievement of remission in 
large vessel or CNS vasculitis, followed by a slow tapering schedule to the lowest effective 
dose which sustains remission, under close clinical and laboratory follow up (Bruton et al, 
2005; Hatemi et al, 2008; Li Thi Huong, 1995; Sharaf & Yazici, 2009). 
4.3 Azathioprine 
Azathioprine is a prodrug of 6-mercaptopurine, containing an imidazole ring and acts like 
an antimetabolite. Azathioprine and mercaptopurine appear to induce immunosuppression 
by interfering with purine nucleic acid metabolism. The drug intervenes with the process of 
cell division at steps that are required for lymphoid cell proliferation following antigenic 
stimulation. Stimulated lymphoid cells incapable of entering cell mitotic phase undergo 
apoptosis, establishing a relevant state of immunosuppression. Although RNA synthesis is 
blocked at the same time, these agents appear to have less effect on cell function if 
implemented after antigen exposure than on nucleic acid synthesis in proliferating, antigen 
encountering, T cells (Bruton et al, 2005). 
The efficacy of azathioprine in ABD is well established. The usual dose is 1-2.5 mg/kg/day 
(not exceeding 200 mg/day) and an average of 3 months is required for its effect to be 
established. This slow immunomodulating action limits the use of azathioprine as a sole 
agent of therapy in acute vasculitis presentation. However, it can be used additionally in the 
acute phase as a corticosteroid sparing agent, as well as prophylactically. Yazici H et al 
propose azathioprine as a first line therapy for non-life-threatening cases of neurological 
complications (Yazici H et al, 1990). According to the EULAR recommendations, 
azathioprine should be used in any ABD patient having inflammatory eye disease with 
posterior segment involvement (Hatemi et al, 2008). Its efficacy and safety was evaluated in 
a randomized, double-blind, placebo-controlled trial. In this trial, there were fewer  
new cases of ocular involvement in azathioprine plus corticosteroids group comparative  
to corticosteroids alone (one versus eight). Additionally, the patients taking azathioprine 
had less frequent oral ulcers, genital ulcers and arthritis (Yazici H et al, 1990). 
Contemplating the pathophysiology of ABD (see above), immunosuppressants like 
azathioprine may play a role in the management of vessel thrombosis through anti-
inflammatory action on vessel wall. Results from Sharaf et al confirm the clinical experience 
that by dampening immune system activation, pro-thrombotic diathesis can be, at least 
partially, reversed (Sharaf & Yazici, 2009). 
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In general, azathioprine could be used as a first line treatment in combination with 
corticosteroids in almost all serious manifestations of the disease and is preferable for 
maintenance therapy after remission induction. Common side effects are gastrointestinal 
disturbances, liver toxicity and bone marrow suppression but rarely do they lead to drug 
discontinuation. In parallel, due to B cell impairment and mild hypoglobulinemia, humoral 
immunity can be weakened by these cytotoxic agents as well. 
4.4 Cyclophosphamide (CyP) 
Cyclophosphamide is a highly active alkylating agent, which impairs DNA duplication and 
cell division. Although it is not a cell specific drug, the greater effect is observed upon 
rapidly proliferating cells, such as T cell clones after their encounter with the antigen. 
Initially, cyclophosphamide has proven a reliable agent in management of lupus nephritis 
and ANCA associated vasculitis and, eventually, has found a distinguished place in ABD 
vasculitis (Bruton et al, 2005).   
It has been known that pulse CyP, combined with intravenous C/S regimen, help to achieve 
remission in ABD vascular and/or visceral involvement (Du et al, 1990; Hamza et al, 1992). 
According to EULAR recommendations, large vessel vasculitis, such as pulmonary and/or 
peripheral aneurysms, need to be treated with CyP for at least 2 years (Hatemi et al, 2008). 
The drug may be administrated either intravenously, as pulse treatment in doses 400-
700mg/m2, or orally in doses of 1-3 mg/day. The exact dose depends upon the severity of 
the disease and considerations of renal and hepatic impairment. Deep immunosuppression 
following CyP administration has a life-saving effect. Also in a double-blind cross over trial, 
CyP has proven beneficial in patients with intractable uveitis (Davatchi et al, 1999).  
Due to its severe toxicity (bone marrow suppression, mucositis, neurotoxicity, syndrome of 
inappropriate ADH secretion, cancer), this drug must be used in life-threatening or non-
responding cases. We prefer to administer CyP intravenously, as monthly or 3-weekly 
pulses of 500-1000mgr bolus, in order to partially avoid bladder toxicity. For safety reasons, 
mesna (chelic agent) and adequate fluids must be administered concurrently. 
4.5 Cyclosporine 
Cyclosporine is a cyclic polypeptide, which forms a complex with cyclophylin, an 
intracellular factor mediating signaling pathways. This complex binds to calcineurin and 
inhibits Ca2+-stimulated dephosphorylation of the cytosolic component of the transcription 
factor NFAT. Activated cytoplasmic NFAT translocates to the nucleus and binds to nuclear 
components required for complete T-cell activation, blocking of IL-2 and other Th1 cytokine 
producing genes (Th1 to Th2 switch). Besides this, calcineurin also possess peptidyl-prolyl 
cis-trans-isomerase enzymatic activity. The peptidyl-prolyl cis-trans-isomerase domain of 
calcineurin facilitates binding to CD147, also known as an inducer of extracellular-matrix 
metalloproteinases (MMPs). This binding causes CD147 to translocate to the cell surface, 
where it plays a critical role in stimulating matrix-metalloproteinase activity, leading to 
matrix degradation. Thus, this agent inhibits the enzymatic activation of MMPs, which leads 
to vessel wall thinning (Weintraub, 2009). Cyclosporine is effective against T-cell–dependent 
immune reactions and a suitable drug for immune intervention in the pathophysiological 
process of ABD vasculitis (see above). Additionally, cyclosporine, in synergy with C/S, 
downregulates the activity of NKT cells controlling inflammatory process (Bruton et al, 
2005; Chi et al, 2010). 
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The efficacy of cyclosporine in ABD has been evaluated primarily in patients with ocular, 
mucocutaneous and articular manifestations. Approximately 50% of patients showed 
clinical remission when treated with cyclosporine. Two well designed trials proved that 
cyclosporine protects ocular degeneration and visual acuity better than conventional 
regimen containing prednisolone (Atmaca, 1994; Ernakova, 2003). A direct comparison of 
the therapeutic potential of cyclosporine to oral cyclophosphamide was conducted by 
Ozyazgan Y et al in patients with ocular inflammation. Therapeutic superiority concerning 
visual acuity was seen in the cyclosporine group at six months, but similar results were 
noted for both agents at two years (Ozyazgan et al, 1992). Similarly, comparison of 
cyclosporine with glucocorticoids or chloramboucil indicates its superiority to control ocular 
symptoms. EULAR recommendations suggest cyclosporine or infliximab in combination 
with azathioprine and corticosteroids for refractory eye involvement and major vessel 
disease as well (strength of recommendation C) (Hatemi et al, 2008). 
Side effects are hypertension, nephrotoxicity and predisposition to infections. Furthermore, 
the role of cyclosporine in vascular neurological involvement in ABD has not been clarified 
yet and its use is discouraged (Bruton et al, 2005). 
4.6 Colchicine 
Colchicine exerts a variety of pharmacological effects, especially in cellular immunity. The 
drug arrests cell division in G1 phase by interfering with microtubule and spindle 
formation. This anti-mitotic effect is greatest on cells with rapid turnover (e.g. neutrophils 
and expanding lymphocyte clones). Colchicine also renders cell membranes more rigid and 
decreases the secretion of chemotactic factors from activated neutrophils, thus inhibiting 
inflammation in many ways (Actulga et al, 1980; Bruton et al, 2005).  
Clinical experience and randomized trials support that the use of colchicine, alone or in 
combination with penicillin, is beneficial in reducing the number of episodes of aphthous 
mucositis and arthritis (Al Waiz et al, 2005). According to the authors’ opinion and EULAR 
recommendations, colchicine has no role in severe large vessel vasculitis management and 
in acute relapses. Slow onset of action and lack of T cell specificity render this drug 
improper for use in severe cases. Beyond that, there is strong recommendation (category Ib) 
for the management of cases where the dominant lesion is erythema nodosum (medium size 
vasculitis) (Hatemi et al, 2008).  
Side effects of colchicine such as nausea, vomiting, diarrhea and hematologic disturbances 
are well controlled with stepwise use of the drug. 
4.7 Methotrexate (MTX) 
Methotrexate competitively inhibits dihydrofolate reductase (DHFR), an enzyme that 
participates in the tetrahydrofolate synthesis. Methotrexate acts specifically during DNA and 
RNA synthesis and, thus, it is cytotoxic during the S-phase of the cell cycle. MTX, by inhibiting 
the enzymes involved in purine metabolism, and leads to intracellular accumulation of 
adenosine and suppression of intercellular adhesion molecule expression by T cells. These two 
mechanisms provoke T cell inhibition (Bruton et al, 2005; Johnston et al, 2005).  
Concerning ABD vasculitis, literature for MTX is relatively poor. However, Borhani 
Haghighi A proposes MTX as a first line therapy in neurological complications (Borhani 
Haghighi, 2009). The relatively low cost and the acceptable safety profile make MTX a 
preferable choice (Davatchi et al, 2003; Kikuchi et al, 2003). EULAR committee recommends 
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MTX for CNS involvement (strength of recommendation C), but no distinction is made 
between vascular and parenchymal involvement (Hatemi et al, 2008). Common side effects 
are liver toxicity and macrocytosis.  
4.8 Biologic agents 
4.8.1 Interferon 
Although interferons (alpha, beta, and gamma) were identified by their antiviral activity, 
these agents also have important immunomodulatory functions. Interferons bind to 
membrane receptors type I and II and produce their immunomodulating effects through a 
cascade of gene induction and transcriptional changes. The final result is enhancement of 
macrophage phagocytic activity and augmentation of specific cytotoxicity by CD8+T 
lymphocytes. How these changes modify immune system reaction in ABD has not  
been clarified. Possible mechanisms include reduction of viral antigen load and 
antiproliferative properties on lymphocytes and damaged tissue cells. Another probable 
mechanism of action is the up-regulation of sTNF-ǂ-RII (soluble TNF-ǂ receptor) and IL-1ra 
(interleukin 1 receptor antagonist). It should be emphasized that other studies entangle IFN-
ǂ action in the induction and propagation of autoimmune process (Kotter et al, 2004; 
Theofilopoulos et al, 2005). 
In a systematic review by Kotter I et al, the authors concluded that nearly all patients with 
mucocutaneous symptoms and/or arthritis and/ or uveitis responded to IFN-ǂ 
administration in a dose related manner (Kotter et al, 2004). Additionally, in other studies 
including cases of refractory uveitis, IFN-ǂ had similar positive results. These reports were 
confirmed by Tugal–Tutkun et al, although they reported lower rates of complete response 
(Tugal-Tutkun et al, 2006). EULAR committee justifies the use of IFN-ǂ with or without 
corticosteroids for eye disease, instead of cyclosporine or azathioprine. On the contrary, 
EULAR recommendations do not consider the use of IFN-ǂ for major artery vasculitis due to 
insufficient data from large studies (Hatemi et al, 2008). We consider that potent, traditional 
immunosuppressants are preferable in these cases and that administration of an agent with 
parallel immunostimulant properties in full-blown inflammation is ambiguous (Boura et al, 
2006). Side effects of IFN-ǂ include psychosis, nausea, vomiting, diarrhea, hematologic 
changes, liver toxicity and leucoencephalopathy (Bruton et al, 2005).  
4.8.2 Anti – TNF- α (tumor necrosis factor) agents 
TNF-ǂ, as a pro-inflammatory cytokine, promotes immune reactions and inflammation. 
Infliximab is a chimeric anti–TNF-ǂ monoclonal antibody, which binds with high affinity to 
TNF-ǂ and prevents the cytokine from binding to its receptors. A number of studies 
(uncontrolled, open labeled, case series and reports) indicate that infliximab control 
mucocutaneous, joint, neural, gastrointestinal and eye manifestations of disease, inducing 
remission (Boura et al, 2006; Sfikakis et al, 2001, 2004). Additionally, in these studies, 
infliximab proved adequate to sustain remission in cases refractory to azathioprine and/or 
cyclosporine. Sfikakis et al propose infliximab as a second line therapy for ABD relapses 
when usual therapy fails or as a first line regimen in severe sight-threatening uveitis 
(Sfikakis et al, 2004). Our experience is in agreement. 
Etanercept contains the ligand binding portion of a human TNF-ǂ receptor fused to the Fc 
portion of human IgG1, and binds to TNF-ǂ, thus preventing it from interacting with its 
receptors. Melikoglu M et al conducted a controlled study using etanarcept in ABD. 
www.intechopen.com
 
Immunopathogenesis Based Adamantiades-Behcet Disease Vasculitis Treatment 
 
183 
Etanercept was superior to placebo in controlling oral ABD manifestations, whereas the rate 
of genital ulcers healing, joint symptoms and papulopustular skin lesions were not 
statistically different between the two groups (Melikoglu et al, 2005). Different results were 
reported from the Study Group on Autoimmune Diseases (GEAS), who published an 
impressive rate of response in ABD using etanercept (96%), (Ramos-Casals et al, 2008). 
These contradictory results indicate that more studies need to be undertaken in order to 
assess etanercept in ABD. 
Like infliximab and etanercept, adalimumab binds to TNF-ǂ, preventing it from activating 
TNF-ǂ receptors. There is an increasing number of reports that adalimumab is promising on 
patients with symptoms refractory to other agents (Bawazeer et al, 2010). EULAR 
recommendations include anti TNF-ǂ agents in possible therapeutic regimens for 
gastrointestinal and CNS involvement, but no mention is made for major vessel 
inflammation (Hatemi et al, 2008). 
Side effects (infections, cancer) and cost must be taken into account. TNF-ǂ antagonists 
could be reserved as a second line therapy in intractable posterior uveitis and CNS vascular 
disease as well. 
4.8.3 Anakinra (anti-interleukin-1) 
IL-1 mediates its pro-inflammatory actions through IL-1 receptor binding on the surface of 
immunocompetent cells. For homeostatic reasons there is a naturally occurring IL-1 receptor 
antagonist (IL-1ra) in serum, which competes with IL-1 for receptor binding, blocks IL-1 
activity and ameliorates its pro-inflammatory actions. The balance between IL-1 and IL-1ra 
may contribute to the extent of an inflammatory response. Anakinra, a recombinant non-
glycosylated version of human IL-1 receptor antagonist, may have a therapeutic role in 
ABD. Although literature is limited, a case report of a patient with severe vascular and 
gastrointestinal ABD, refractory to conventional treatment, who responded only to anakinra 
has been published (Botsios et al, 2008). However, later reports question the long term 
efficacy of anakinra in preventing secondary complications, such as amyloidosis (Bilginer et 
al, 2010). These ambiguous results confirm the view that further studies are needed. 
4.9 Other treatments  
There are limited data available regarding the use of alternative therapeutic options in ABD. 
Intravenous immunoglobulins have been tested either in a small number of patients or in a 
heterogeneous group of patients with eye inflammation (Seider et al, 2001).  
IL-6 plays a central role in disease pathophysiology. IL-6 levels have been reported to be 
elevated in the cerebrospinal fluid of patients with active CNS disease. Probably anti–IL-6 
treatment could be useful in vascular manifestations of ABD. In fact, Borhani Haghighi A 
proposed tocilizumab (anti-interleukin-6 agent), as an additional weapon to the therapeutic 
armentarium (Borhani Haghighi & Safari, 2008).  
Lim SH and de Cata A reported resolution of ABD manifestations after non myeloablative 
hematopoietic stem cell transplantation (autologous or derived from allogeneic bone 
marrow or umbilical cord blood). There is an increasing number of studies proposing this 
practice as an upcoming treatment for refractory ABD. The rational is the depletion of 
activated immune cells from the body (De Cata et al, 2007; Lim et al, 2009)  
All these therapeutic modalities have not been tested adequately and are not mentioned in 
current guidelines.  
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5. Specific considerations for vascular inflammation in ABD  
5.1 Major vessel involvement  
Although large artery disease is uncommon in ABD, it can lead to significant morbidity and 
mortality. The percentage of ABD patients with arterial damage varies from 5 to 18%. The 
two main presentations of arterial involvement is lumen stenosis, or more likely, aneurysm 
formation.  
Although pathogenesis is yet unclear, the hypothetical model already proposed for other 
large vessel vasculitides might be of value. According to this model, IL-1 and TNF-ǂ 
secretion from dendritic cells, macrophages and neutrophils results in the production of 
radical oxygen species and mettalloproteinases with subsequent elastic fiber destruction, 
thinning of media layer and expansive remodeling of the artery (Weyand & Goronzy, 2003). 
Chronic uncontrolled inflammation also leads also to arterial occlusions due to intimal 
thickening. These two forms of vessel remodeling may be detected in the same patient 
(Buggage et al, 2005).    
Aneurysm formation and/or occlusive lesions may require combined medical and surgical 
intervention under the supervision of an experienced clinical immunologist. Urgent surgery 
is mandatory in case of enlarging or ruptured aneurysms or due to organ-threatening 
ischemia. Equally significant is the implementation of postoperative immunosuppressive 
therapy, to prevent relapse and common complications after arterial bypass surgery, such as 
graft occlusion and new aneurysm formation at the site of anastomosis (Calamia et al, 2011; 
Tuzun et al, 1997). 
The first goal is to achieve remission with immunosuppressive drugs. We suggest 
aggressive therapy with methylprednisolone 1000mg x 3 or more consecutive days, 
followed by oral C/S and CyP in intravenous pulse treatment (4-8mg/kg) until clinical and 
laboratory remission.  
A number of patients with major-vessel arterial disease were studied in a retrospective 
manner. This study illustrated that C/S, even in high doses, did not improve occlusive 
disease when fibrosis of intima was irreversible, emphasizing the importance of early 
immune intervention (Le Thi Huong, 1999).  
Anticoagulation is employed successfully in several cases, but EULAR committee do not 
recommend anticoagulants or antiplatelet drugs due to lack of evidence from randomized 
controlled trials and possible danger of bleeding in sites of aneurysmal rupture (Hatemi et 
al, 2008). (see algorithm 1) 
5.2 Medium - small vessel involvement  
Although large vessel involvement is responsible for deaths in ABD, small and medium 
vessel vasculitis maintains the main characteristic in disease pathophysiology. Pathological 
findings compatible with vasculitis from different anatomical sites have been reported. 
More specifically, the histopathological findings range from minor neutrophilic vascular 
infiltration to true leukocytoclastic (oral lesions) or lymphocytic (genital lesions) vasculitis. 
Although such interesting clues indicate a variance in the pathophysiologic process, there 
are no data to suggest different therapeutic approaches in patients with different type of 
lesions (Chun et al, 1990; Nazarro et al, 1966).  
Retinal vasculitis is a serious finding in posterior uveitis of ABD patients. EULAR committee 
recommends a treatment regimen that includes azathioprine and systemic corticosteroids 
for the management of the first attack. Doses of prednisone up to 1 mg/kg/day for one 
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month with tapering thereafter as tolerated proved to be adequate in most of the cases. 
Furthermore, long term follow-up of patients proves that local and/or systemic 
corticosteroids and azathioprine are beneficial for maintenance treatment as well (Hatemi et 
al, 2008; Iscan et al, 2005; Yazici et al, 2010). 
In severe relapsing or refractory eye inflammation, initial pulse therapy with intravenous 
methylprednisolone (1 g/day for three days or more) is needed. A number of observational 
studies have suggested efficacy of infliximab for the treatment of inflammatory eye disease. 
Combination of the above agents with cyclosporine or IFN-ǂ can be used for intractable eye 
inflammation (EULAR recommendations 1 and 2), although the level of evidence is low 
(grade of evidence III) (Hatemi et al, 2008; Yazici et al, 2010).  
Alternatively, the addition of cyclophosphamide pulse treatment prior to infliximab in 
refractory ocular ABD could be used. There is a possible synergistic effect of 
cyclophosphamide and infliximab in controlling ocular inflammation when used 
consecutively (submitted for publication). 
In general, neurological complications could be treated in the same manner as posterior 
uveitis. The combination of high-dose C/S (3–7 pulses of intravenous methylprednisolone 1 
g/day) with another immunosuppressive agent (preferably azathioprine) is required. 
Cyclophosphamide, methotrexate and TNF-ǂ antagonists represent quite useful alternatives 
in severe parenchymal disease. For dural sinus thrombosis, short pulses of intravenous C/S 
are usually adequate. In neurological involvement, cyclosporine should not be introduced 
due to its potential neurotoxicity (strength of recommendation C) (Borhani Haghighi, 2009; 
Borhani-Haghighi & Safari, 2010; Hatemi et al, 2008; Kotter et al, 2006). 
Serious renal lesions are rare and range from minor IgA deposits in glomerulus to catastrophic 
crescentic glomerulonephritis. In case of clinically important glomerulonephritis, treatment 
varies according to other organ involvement. A reasonable approach is cyclophosphamide 
750-1000 mg /month plus glucocorticosteroids 500-1000 mg /day for three days and 60-100 
mg oral prednisolone in tapering doses until clinical remission (Altiparmak et al, 2001).  
(see algorithm 2) 
5.3 Venous thrombosis 
Deep vein thrombosis (DVT) is the most frequent vascular manifestation of ABD. DVT is 
believed to result from endothelial inflammation leading to thrombosis through pro–
thrombotic alterations in the vessel wall, upregulation of adhesion molecules and 
endothelial dysfunction. DVT can occur in any site of the vascular tree, most commonly in 
lower extremities, but also in hepatic veins, cerebral venous sinuses, superior and inferior 
vena cava (Ames et al, 2001).  
Thrombotic events are prevented by ameliorating systemic inflammation, rather than by the 
institution of primary anticoagulation (Kuzu et al, 1994; Mader et al, 1999; Sarica-Kucukoglu 
et al, 2006). EULAR does not recommend the use of antiplatelet drugs, anticoagulants or 
fibrinolytic agents for thrombotic events in ABD, due to insufficient data from large studies 
(Hatemi et al, 2008).  
The authors suggest that venous thrombosis must be faced on case-by-case basis, through 
cooperation with appropriate subspecialists. When anti-thrombotic intervention is 
considered, aspirin is a rational choice. Acetylosalicylic acid interferes with the 
transcriptional activation of the interferon-Ǆ gene, a mechanism of action that may be 
www.intechopen.com
 
Advances in the Diagnosis and Treatment of Vasculitis 
 
186 
particularly useful in inhibiting T-cell function in ABD. Furthermore, from the 
pathophysiological models of giant cell arteritis, we know that IFN-Ǆ favor intimal 
hyperplasia and endothelial dysfunction. (see algorithm 1) 
 
 
 
 
 
 
 
Target Therapeutic Goals Current or emerging approach 
Interleukin-1 Suppression of acute phase 
response 
Inhibition of macrophages 
Anakinra, C/S 
 
Interleukin-6 Suppression of acute phase 
response 
Inhibition of macrophages 
Tocilizumab,  C/S 
Interferon-Ǆ or 
interferon– Ǆ 
inducing genes 
Disruption of adaptive 
T-cell response 
acetosalicylic acid,  C/S 
Metalloproteinases Inhibition of matrix 
degradation- 
-inhibition of expanding 
remodeling 
Cyclosporine 
Innate immune 
responses 
Inhibition of nuclear factor k-
B 
C/S, Interferons 
Adaptive immune 
responses 
Inhibition of T cell clones  
activation 
Cyclophosphamide, Cyclosporine 
Vascular thrombosis Inhibition of prothrombotic 
changes of endothelium 
acetosalicylic acid, anticoagulants, 
immunosuppressants 
TNF-ǂ Inhibition of TNF-ǂ 
mediated immune response 
etanercept, infliximab, adalimumab 
 
 
 
 
 
 
 
Table 3. Therapeutic targets for pathogenic pathways in Adamantiades- Behcet disease and 
indicative approaches 
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Algorithm 1. Therapeutic intervention for major vessel involvement in ABD. 
 
Major vessel 
involvement 
 
Aneurysms 
and/or occlusion
 
Deep venous 
thrombosis 
(DVT) 
 
 
Urgent invasive 
repair 
 
 
CyP + CS pulses
Post-operative 
immunosuppress
ion 
Oral CS + AZA 
Response 
Maintenance 
treatment 
Oral CS + AZA
 
No response 
 
Invasive repair
 
Extremities 
CS + AZA + 
Aspirin 
 
Central veins 
Pulses CyP + CS 
+ Aspirin 
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Algorithm 2. Therapeutic intervention for visceral involvement (eye, CNS) in ABD. 
6. Conclusions 
The multi-level pathogenetic process of visceral ABD implies that inflammation control by one 
single agent is seemingly impossible; indeed, various combinations of immunomodulating 
agents are proposed.  
Early administration of immunosuppressive therapy is critical before permanent damage is 
established. Invasive approaches must be implemented when needed.  
Urgent intervention is mandatory in life threatening circumstances.  
Although there is an increasing amount of data from controlled trials regarding specific 
issues in ABD therapy (targeting management of early ABD and particular disease 
mechanisms), current guidelines are largely based on the opinion of experts. 
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